Lilly was one of four pharma companies to appear at the FDA Part 15 Meeting on Social Media and Medical Product promotion held on November 12 and 13 in Washington DC. Lilly offered comprehensive comments, including citing the fact that the current system of keeping up with developments in digital media from a regulatory perspective needs fixing. (less info)